{
    "root": "2e80ce80-c964-8dbb-e063-6394a90ae43b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Enalapril Maleate",
    "value": "20250219",
    "ingredients": [
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "ENALAPRIL MALEATE",
            "code": "9O25354EPJ"
        }
    ],
    "indications": null,
    "contraindications": null,
    "warningsAndPrecautions": "Enalapril Maleate Tablets, USP 10 mg\n                  Red, rounded triangle shaped scored tablet debossed with “S 7” on one side and scored on the other side.\n                  NDC 72789-329-90 Bottle of 90\n                  \n                     Storage\n                  \n                  Store at 20\n \n  oto 25\n \n  oC (68\n \n  oto 77\n \n  oF); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n\n \n                  Keep container tightly closed.\n                  Protect from moisture.\n                  Dispense in a tight container as per USP, if product package is subdivided.",
    "adverseReactions": "Enalapril maleate tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.\n                  Do not coadminister aliskiren with enalapril maleate tablets in patients with diabetes (see\n \n  \n                        PRECAUTIONS, Drug Interactions\n                     ).\n\n \n                  Enalapril maleate tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see\n \n  \n                        WARNINGS, Head and Neck Angioedema\n                     )."
}